Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation

Anticancer Research

Volumn 16, Issue 4 A, 1996, Pages 2083-2088

  Buggia, Isabella ^a   Zecca, Marco ^a   Alessandrinq, Emilio Paolo ^a   Locatelli, Franco ^a   Rosti, Gianantonio ^b   Bosi, Alberto ^c   Pession, Andrea ^d   Rotoli, Bruno ^e   Majolino, Ignazio ^f   Dallorso, Alessandro ^g   Regazzi, Mario B ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c CAREGGI UNIVERSITY HOSPITAL   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^g G GASLINI INSTITUTE   (Italy)

Author keywords

Antifungal treatment; Bone marrow transplantation; Busulfan; Conditioning regimen; Drug drug interaction; Itraconazole; Pharmacokinetics

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYTOCHROME P450; ETOPOSIDE; FLUCONAZOLE; ITRACONAZOLE; LIPOXYGENASE; MELPHALAN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFECT; DRUG METABOLISM; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MYCOSIS; ORAL DRUG ADMINISTRATION; OXIDATION; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; BONE MARROW TRANSPLANTATION; BUSULFAN; CHILD; CHILD, PRESCHOOL; DRUG INTERACTIONS; FEMALE; FLUCONAZOLE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; ITRACONAZOLE; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 9444277948     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Santos GW, Tutschka PJ, Brookmeyer R, Saral R, Bcschorner W, Bias WB, Braine HG, Burns WH, Elfenbein GJ, Kaizer H, Mellits D, Sensenbrenner LL, Stuart RK, Yeager AM: Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 309: 1347, 1983.
2. Parkman R, Rappeport JM, Hellman S, Lipton J, Smith B, Geha R, Nathan DG' Busulfan and total body irradiation as antihematopoietic stem cell agents in the preparation of patients with congenital hone marrow disorders for allogeneic bone marrow transplantation. Blood 64: 852, 1984.
3. ITutschka PJ, Copelan EA, Klein JP: Bone marrow transplantation for leukemia following a new husulfan and cyclophosphamide regimen. Blood 70: 1382, 1987.
4. Lucarelli G, Galimberti M, Ponchi P, Andelucci E, Baronciani D, Giardini C, Politi P, Durazzi SMT, Muretto P, Albertini F: Bone marrow transplantation in patients with thalassemia. Engl J Med 322: 417, 1990.
5. 2 the appropriate dosage of busulfan in children undergoing hone marrow transplantation? Blood 79: 2475-2479, 1992.
6. Yeager AM, Wagner JE, Graham ML, Jones RJ, Santos GW, Grocnow LB: Optimization of busuifan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation. Blood 80: 24252428, 1992.
7. Grochow LB, Krivit W, Whitley CB, Blazar B: Busulfan disposition in childlen. Blood 75: 1723- 1727, 1990.
8. Vassal G, Fischer A, Challine D, Boiand I, Ledheist F, Lemerie S, Vilmer E, Rahimy C, Souillet G, Giuckman E, Michel G, Deroussent A, Gouyette A: Busulfan disposition below the age of three: alteration in children with lysosomal storage disease. Blood 82: 1030-1034, 1993.
9. Regazzi MB, Locatelli F, Buggia I, Bonetti F, Zecca M, Pregnolato M, Quaglini S: Disposition of high dose busulfan in pediatric patients undergoing bone marrow transplantation. Clin Pharmacol Ther 54: 45-52, 1993
10. Hassan M, Oberg G, Bekassy AN, Aschan J, Ehrsson H, Ljungman P, Lonnerholm G, Smedmyr B, Taube A, Wallin I, Simonsson B: Pharmacokinetics of high-dose busulfan in relation to age and chronopharmacology. Cancer Chemother Pharmacol 28: 130, 1991.
11. Shaw PJ, Scharping CE, Brian RJ, Earl JW: Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia. Blood 84: 2357-2362, 1994.
12. Hassan M, Ljungman P, Bolme P, Ringden O, Syruckova Z, Bekassy A, Stary J, Wallin I, Kallberg N: Busulfan bioavailability. Blood 84: 2144-2150, 1994.
13. Friis-Hansen B: Body water compartments in children: Changes during growth and related changes in body composition. Pediatrics 28: 169, 1961.
14. 14C-busulfan in isolated perfused rat liver. Eur J Drug Metab Pharmacokinet 12: 71, 1987.
15. Buggia I, Locatelli F, Regazi MB and Zecca M. Busulfan: The Annals of Pharmacotherapy 28: 1055-1062, 1994.
16. Hassan M, Oberg G, Ehrsson H, Ehrnebo M, Wallin I, Smedmyr B, Totterman T, Eksborg S, Simonsson B: Pharmacokinetic and metabolic studies of high-dose busulfan in adults. Eur J Clin Pharmacol 36: 525, 1989.
17. Ehrsson H, Hassan M: Binding of busulfan to plasma proteins and blood cells. J Pharm Pharmacol 36: 694, 1984.
18. 11C-busulfan in cynomolgus monkey and in the brain of a human patient. Cancer Chemother Pharmacol 30: 81, 1992.
19. Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA, Thomas ED: Regimen related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 6: 1562-1568. 1988.
20. Vassal G, Deroussent A, Hartmann O, Chalmlinc D, Benhamou E, Valteau-Couanet D, Brugieres L, Kalifa C, Gouyette A, Lemerle J: Dose-dependent neurotoxicity of high-dose busulfan in children: A clinical and pharmacological study. Cancer Res 50: 6203, 1990.
21. MC Donald GB, Sharma P, Matthews DE, Shulman HM, Thomas DE: Venoocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence and predisposing factors. Hepatology 4: 116-22, 1984.
22. Grochow LB, Jones RJ, Brundrett RB, Braine HG, Chen T-L, Saral R, Santos GW, Colvin OM: Pharmacokinetics of busulfan: Correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 25: 55, 1989.
23. Grochow LB, Fiarltadosi S, Sarltos G, Jones R: Busulfan dose adjustment decreases the risk of veno-occlusive disease in patients undergoing hone marrow transplantation. Proc American Assoc Cancer Res 33: 220, 1992.
24. Meresse V, Hartmann O, Vassal G, Benhamou E, Valteau-Couanet D, Brugieres L and Lemerle J: Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containg regimens followed by autologous bone marrow transplantation: a study in 136 children. Bone Marrow Transplantation 10: 135- 141, 1992.
25. Henner WD, Furlong EA, Flaherty MD and Shea TC: Measurement of busulfan in plasma by high-performance liquid chromatography. J of Chromatography 416: 426-432, 1987.
26. P-PHARM User's Guide, 2nd ed. SIMED, Creteil, France 1994.
27. Dempster AP, Laird NM, Rubin DB: J Royal Statisticsal Society 39: 1-38, 1977.
28. Maxwell GM: Paediatric drug dosing: Bodyweight versus surface area. Drugs 37: 113, 1989.
29. Gonzales FJ: Molecular genetics of the P-450 superfamily Pharmacol Ther 30: 287-95, 1990.
30. Back DJ, Tjia JF: Comparative effects of the antimycotic drugs. ketoconazole, flucorazole, itraeonazole ar.d terbinatine on the metabolism of cyclosporine by human liver microsomes. British Journal of Clinical Pharmacology 32: 624-626, 1991.
31. Grant SM, Clissold SP: Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 37: 310-344, 1989.
32. Grant SM, Glissold SP: Fluconazole A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in superficial and systemic mycoses. Drugs 39: 877-916. 1990.
33. Vassal G, Challine D, Koscienly S, Hartmann O, Deroussent A et al: Chronopharmacology of high-dose busulfan in children. Cancer Res 53: 1534- 1537, 1993.
34. Hassan M and Ehrsson H: Urine metabolites of busulfan in the rat. Drug Metabol Dispos 16: 85-92, 1988.
35. Marchand DH and Abdel-Monem MM: Glutathione-S-transferases catalyzed conjugation of 1,4-disubstituted butanes with glutatione in vitro. Biochem Biophys Res Commun 128: 360-367, 1985.
36. Marchand DH, Remmel RP and Abdel-Monem MM: Biliary excretion of a glutathione conjugate of busulfan and 1,4-diiodobutane in the rat. Drug Metabol Dispos 16: 85-92, 1993.
37. Vassal G, Boland I, Deroussent A, Georgin D and Gouyette A. Busulfan metabolisrm in cytosolic and microsomal mouse liver preparations. Proc Am Assoc Cancer Res 34: 268, 1993.
38. Vassal G, Boland I, Deroussent A, Georgin D and Gouyette A: In vitro busulfarl metabolism in human and mouse liver. Proc Am Assoc Cancer Res 34: 2995, 1994.
39. Dekant W, Lash LH and Anders MW: Fate of glutathione conjugates and bioactivation of cysteine S-conjugates by cysteine conjugate b-lyase. In: Helmut H and Ketterer B (eds). Glutathione conjugation, mechanisms and biological significance. London, Academic Press, Ltd 1988, pp 415-449.
40. Hinson J and Kadlubar FF: Glutathione and glutathione transferases in the detoxification of drug and carcinogen metabolites In: Helmut H and Ketterer B (eds), Glutathione conjugation, mechanisms and biological significance. London, Academic Press, Ltd 1988, pp236-280.
41. Schuler U, Schroer S, Kuhnle A, Blanz J, Mewes K, Kumbier I, Proksch B, Zeller & Ehninger G: Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted? Bone Marrow Transplantation 14: 759-765, 1994.
42. Regazzi MB, Locatelli F, Buggia I, Alessandrino EP, Zecca M, Troletti D, Bonetti F, Pession A, Dallorso S, Bosi A, Maiolino J, Fontana R, Rosti C: Clinical pharmacokinetics-pharmacodynamics of busulfan. Therapie. Suppl Abstract of EACPT (abs. n. 281), 1995.